SUPN - Company ID 0001356576
The table below shows SUPERNUS PHARMACEUTICALS, INC.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $184.87M | $151.37M | $144.71M | $115.85M | $31.67M | $52.09M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $182.18M | $171.25M | $140.83M | $145.64M | $145.41M | $152.49M |
| Inventory | $110.77M | $107.10M | $44.02M | $49.42M | $63.98M | $68.16M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $731.58M |
| $593.89M |
| $738.87M |
| $687.58M |
| $640.00M |
| $591.00M |
| Property, plant & equipment | $10.04M | $10.63M | $11.07M | $11.34M | $11.88M | $12.27M |
| Goodwill | $120.67M | $119.08M | $117.02M | $117.02M | $117.02M | $117.02M |
| Total assets | $1.50B | $1.42B | $1.38B | $1.35B | $1.34B | $1.32B |
| Accounts payable | $10.17M | $8.18M | $8.21M | $7.07M | $6.39M | $4.63M |
| Total current liabilities | $373.93M | $330.63M | $286.36M | $281.77M | $291.51M | $308.66M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $423.92M | $370.09M | $318.50M | $316.58M | $335.55M | $358.38M |
| Retained earnings | $515.58M | $521.98M | $567.10M | $544.60M | $541.10M | $502.60M |
| Total equity | $1.08B | $1.05B | $1.06B | $1.03B | $1.01B | $957.45M |